Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 3,000 hematologic oncology specialists to participate in the upcoming Eleventh Annual Meeting of the Society (SOHO 2023). Click for more information and registration.

Register now
  • 6,992 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News


All Sessions will remain available on the Attendee Hub until October 1, 2023. Sessions are accessed through the Home page.

Early MRD Testing After CAR-T May Be Prognostic in Multiple Myeloma

Early testing of MRD in bone marrow after CAR-T in MM could potentially provide prognostic information

Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain-DLBCL Therapies May Not Be Cost Effective

This all-new episode of The HemOnc Pulse features Anca Prica and Abi Vijenthira, MD, discussing their analysis on the cost-effectiveness of DLBCL therapies with host Chadi Nabhan.

Tisagenlecleucel Shows Long-Term Safety, Efficacy in Pediatric ALL

Tisagenlecleucel may be a “curative treatment option” for children and young adults with heavily pretreated R/R ALL.

NS7CAR Shows Efficacy in T-Cell ALL, LBL

A CD7-targeted CAR T-cell therapy was “safe and highly effective” in patients with heavily pretreated T-cell ALL or T-cell LBL.

Axicabtagene Ciloleucel Leads to ‘Continued Durable Responses’ in ZUMA-5

Axicabtagene ciloleucel showed a three-year OS rate of 75% in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Study Analyzes Immunotherapy Response Biomarkers in MDS

Certain cellular pathways were upregulated in patients with MDS who responded to immunotherapy and downregulated in those who did not

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top